Compare UHT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHT | ACRS |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.1M | 529.9M |
| IPO Year | 1995 | 2015 |
| Metric | UHT | ACRS |
|---|---|---|
| Price | $39.00 | $3.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | 115.3K | ★ 3.1M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.68% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $99,190,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.18 | N/A |
| P/E Ratio | $49.80 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $36.07 | $2.10 |
| 52 Week High | $46.30 | $6.60 |
| Indicator | UHT | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 46.40 |
| Support Level | $38.42 | $3.18 |
| Resistance Level | $38.98 | $4.67 |
| Average True Range (ATR) | 1.03 | 0.28 |
| MACD | 0.28 | 0.07 |
| Stochastic Oscillator | 72.29 | 72.03 |
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.